Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol™) in murine and human breast cancer cell lines

被引:86
|
作者
Zaks-Zilberman, M
Zaks, TZ
Vogel, SN
机构
[1] Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA
[2] NCI, Surg Branch, Bethesda, MD 20892 USA
关键词
breast cancer; inflammatory genes; LPS; macrophages; paclitaxel;
D O I
10.1006/cyto.2001.0935
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In murine macrophages, the anti-tumor agent, paclitaxel, induces expression of a wide variety of inflammatory and anti-inflammatory genes, and causes cytokine secretion via signaling pathways that overlap with those engaged by lipopolysaccharide (LPS), the endotoxic component of Gram-negative bacteria. Using semi-quantitative RT-PCR for detection of gene expression, coupled with ELISA for the detection of secreted gene products, we analyzed the responsiveness of an extensive panel of cytokine and non-cytokine genes to induction by paclitaxel and LPS in the murine DA-3 breast cancer line. A subset of the genes examined (e.g., G-CSF, MIP-2, iNOS, and EL-1 beta, and GM-CSF) was upregulated >3-20-fold by both LPS and paclitaxel in the DA-3 cell line, while IP-10 mRNA was induced by paclitaxel, but not by LPS. In the human MDA-MB-231 breast cancer cell line, LPS also increased mRNA levels for both GM-CSF and IP-10 significantly, while, paclitaxel increased IP-10 mRNA levels with delayed kinetics and failed to induce GM-CSF mRNA. Co-cultures of murine breast cancer cells and macrophages, stimulated with IFN-gamma plus either paclitaxel or LPS, resulted in augmented release of nitric oxide. As both GM-CSF and IP-10 have been implicated in tumor rejection in vivo through either indirect actions on the host immune system or by inhibiting tumor angiogenesis, our data strengthen the hypothesis that tumor cell-derived inflammatory mediators may, in part, underlie the anti-tumor efficacy of paclitaxel in breast cancer. (C) 2001 Academic Press.
引用
收藏
页码:156 / 165
页数:10
相关论文
共 50 条
  • [1] Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines
    Mao, Qi-Qi
    Bai, Yu
    Lin, Yi-Wei
    Zheng, Xiang-Yi
    Qin, Jie
    Yang, Kai
    Xie, Li-Ping
    MOLECULAR NUTRITION & FOOD RESEARCH, 2010, 54 (11) : 1574 - 1584
  • [2] Establishment of a Paclitaxel Resistant Human Breast Cancer Cell Strain (MCF-7/Taxol) and Intracellular Paclitaxel Binding Protein Analysis
    Zuo, K-Q
    Zhang, X-P
    Zou, J.
    Li, D.
    Lv, Z-W
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2010, 38 (04) : 1428 - 1435
  • [3] Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines
    Zhenfeng Duan
    Diana E. Lamendola
    Yifei Duan
    Rushdia Z. Yusuf
    Michael V. Seiden
    Cancer Chemotherapy and Pharmacology, 2005, 55 : 277 - 285
  • [4] Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines
    Duan, ZF
    Lamendola, DE
    Duan, YF
    Yusuf, RZ
    Seiden, MV
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (03) : 277 - 285
  • [5] Limbal stem cell deficiency secondary to systemic paclitaxel (Taxol) for breast cancer: a case report
    Sekhon, Amardeep
    Wang, Jeff Y. F.
    Tan, Johnson C. H.
    Holland, Simon P.
    Yeung, Sonia N.
    BMC OPHTHALMOLOGY, 2020, 20 (01)
  • [6] Limbal stem cell deficiency secondary to systemic paclitaxel (Taxol) for breast cancer: a case report
    Amardeep Sekhon
    Jeff Y. F. Wang
    Johnson C. H. Tan
    Simon P. Holland
    Sonia N. Yeung
    BMC Ophthalmology, 20
  • [7] In vitro synergy of paclitaxel (Taxol) and vinorelbine (Navelbine) against human melanoma cell lines
    Photiou, A
    Shah, P
    Leong, LK
    Moss, J
    Retsas, S
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (03) : 463 - 470
  • [8] A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines
    Blajeski, AL
    Kottke, TJ
    Kaufmann, SH
    EXPERIMENTAL CELL RESEARCH, 2001, 270 (02) : 277 - 288
  • [9] In vitro comparative evaluation of trastuzumab (Herceptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines
    Merlin, JL
    Barberi-Heyob, M
    Bachmann, N
    ANNALS OF ONCOLOGY, 2002, 13 (11) : 1743 - 1748
  • [10] Curcumin and paclitaxel induce cell death in breast cancer cell lines
    Calaf, Gloria M.
    Ponce-Cusi, Richard
    Carrion, Flavio
    ONCOLOGY REPORTS, 2018, 40 (04) : 2381 - 2388